"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA Approves Pembrolizumab (Keytruda) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment

FDA Approves Pembrolizumab (Keytruda) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment

22 Mar 2017 9:10 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved pembrolizumab (Keytruda) for adult and pediatric patients with classical hodgkin lymphoma (cHL) refractory to treatment, or who have relapsed after three or more prior lines of therapy. Read the full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software